RMD

ResMed
D

RMD

Arincen97/100B

ResMed income statement 1993–2027

5.73B USD over the last twelve months, and 5.65B USD in fiscal year 2026.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2026
30 Jun 2026
FY2025
30 Jun 2025
FY2024
30 Jun 2024
FY2023
30 Jun 2023
FY2022
30 Jun 2022
FY2021
30 Jun 2021
FY2020
30 Jun 2020
FY2019
30 Jun 2019
FY2018
30 Jun 2018
FY2017
30 Jun 2017
5.73B5.65B5.15B4.69B4.22B3.58B3.20B2.96B2.61B2.34B2.07B
Revenue growth
+9.04%+9.85%+9.84%+10.95%+18.02%+11.93%+8.11%+13.44%+11.38%+13.23%+12.40%
Cost of revenue
2.23B2.20B2.09B2.03B1.87B1.55B1.36B1.24B1.07B978.03M864.99M
Gross profit
3.51B3.45B3.05B2.66B2.36B2.02B1.84B1.72B1.54B1.36B1.20B
Gross margin
61.18%61.06%59.36%56.67%55.78%56.57%57.53%58.09%58.95%58.21%58.15%
Research and development
393.82M378.29M331.28M307.53M287.64M253.58M225.28M201.95M180.65M155.15M144.47M
Selling, general and administrative
1.17B1.12B991.02M917.14M874.00M739.37M670.39M676.69M645.01M600.37M553.97M
Operating expenses
1.61B1.54B1.37B1.34B1.22B1.02B935.42M908.73M957.32M820.33M775.95M
1.90B1.91B1.69B1.32B1.13B1.00B903.68M809.66M579.26M541.83M425.80M
Operating income growth
+8.86%+13.24%+27.69%+16.61%+13.15%+10.69%+11.61%+39.77%+6.91%+27.25%-0.74%
Operating margin
33.13%33.76%32.75%28.17%26.80%27.96%28.27%27.38%22.22%23.15%20.60%
Interest income
——————362.00K1.02M2.30M16.38M17.09M
Interest expense
——12.61M45.71M47.38M22.31M23.99M40.38M36.16M28.36M28.24M
Other non-operating income
112.68M10.96M-7.80M-55.10M-30.21M-39.80M-20.02M-76.57M-60.42M-20.52M-7.06M
Pretax income
2.01B1.92B1.68B1.26B1.10B960.48M883.66M733.09M518.85M521.31M418.74M
Income tax
418.61M396.12M276.84M243.85M204.11M181.05M409.16M111.41M114.26M205.72M76.46M
Effective tax rate
20.81%20.64%16.50%19.28%18.53%18.85%46.30%15.20%22.02%39.46%18.26%
1.59B1.52B1.40B1.02B897.56M779.44M474.51M621.67M404.59M315.59M342.28M
Net income growth
+10.80%+8.75%+37.20%+13.75%+15.15%+64.26%-23.67%+53.65%+28.20%-7.80%-2.87%
Net margin
27.79%26.94%27.22%21.79%21.25%21.78%14.84%21.02%15.52%13.49%16.56%
Basic shares
145.16M144.71M146.72M147.02M146.77M146.07M145.31M144.34M143.11M142.76M141.36M
145.62M144.98M147.34M147.55M147.46M147.04M146.45M145.65M144.48M143.99M142.45M
Change in diluted shares
-1.09%-1.60%-0.14%+0.06%+0.28%+0.40%+0.55%+0.81%+0.35%+1.08%+0.55%
EPS (basic)
10.9910.449.556.946.125.343.274.312.832.212.42
10.9510.409.516.926.095.303.244.272.802.192.40
EPS growth
+12.08%+9.36%+37.43%+13.63%+14.91%+63.58%-24.12%+52.50%+27.85%-8.75%-3.61%
Dividends per share
2.462.402.121.921.761.681.561.561.481.401.32
Dividend growth
+12.33%+13.21%+10.42%+9.09%+4.76%+7.69%0.00%+5.41%+5.71%+6.06%+10.00%
EBITDA
2.24B2.15B1.91B1.53B1.36B1.18B1.10B990.43M705.80M680.22M568.89M
EBITDA margin
39.07%38.08%37.18%32.73%32.20%32.88%34.53%33.49%27.08%29.07%27.53%
EBIT
2.01B1.91B1.68B1.31B1.16B982.80M912.35M809.06M555.00M560.26M456.73M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about ResMed's income statement

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.